glp 1 blue cross Independence to stop covering GLP-1 agonists Wegovy, Ozempic as weight loss drugs in 2025 GLP-1 | Blue Cross and

Nausea, fatigue, and appetite changes that may have occurred in early weeks typically diminish significantly once your dose is stable

These observations lend support to the hypothesis that GLP-1/GLP-1R axis might directly act on ovarian MGCs to promote the follicular development in a dose-dependent manner, likely contributing to the oocyte maturation in PCOS

One 2024 study in Cell Metabolism showed that a single low dose of GLP-1 reduces inflammation, independent of weight loss

*Correspondence: Adrian Vella, [email protected] Specialty section: This article was submitted to Diabetes, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers